EPO and triple-A syndrome: Formoterol, an inhaled long‐acting β2‐agonist, has been used as a bronchodilator combating asthma and COPD for decades.[31, 32] To explore the mechanisms underlying formoterol protection in EPO‐induced AAA, we examined the expression of β2AR in mouse VSMCs.